Alpha 2.0

» Articles » PMID: 24292634

Pharmacological Inhibition of NOX Reduces Atherosclerotic Lesions, Vascular ROS and Immune-inflammatory Responses in Diabetic Apoe(-/-) Mice

Overview

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2013 Dec 3

PMID 24292634

Citations 31

Authors

Authors

E Di Marco

S P Gray

P Chew

C Koulis

A Ziegler

C Szyndralewiez

R M Touyz

H H H W Schmidt

M E Cooper

R Slattery

K A Jandeleit-Dahm

Affiliations

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Enhanced vascular inflammation, immune cell infiltration and elevated production of reactive oxygen species (ROS) contribute significantly to pro-atherogenic responses in diabetes. We assessed the immunomodulatory role of NADPH oxidase (NOX)-derived ROS in diabetes-accelerated atherosclerosis.

Methods: Diabetes was induced in male Apoe(-/-) mice with five daily doses of streptozotocin (55 mg kg(-1) day(-1)). Atherosclerotic plaque size, markers of ROS and immune cell accumulation were assessed in addition to flow cytometric analyses of cells isolated from the adjacent mediastinal lymph nodes (meLNs). The role of NOX-derived ROS was investigated using the NOX inhibitor, GKT137831 (60 mg/kg per day; gavage) administered to diabetic and non-diabetic Apoe(-/-) mice for 10 weeks.

Results: Diabetes increased atherosclerotic plaque development in the aortic sinus and this correlated with increased lesional accumulation of T cells and CD11c(+) cells and altered T cell activation in the adjacent meLNs. Diabetic Apoe(-/-) mice demonstrated an elevation in vascular ROS production and expression of the proinflammatory markers monocyte chemoattractant protein 1, vascular adhesion molecule 1 and IFNγ. Blockade of NOX-derived ROS using GKT137831 prevented the diabetes-mediated increase in atherosclerotic plaque area and associated vascular T cell infiltration and also significantly reduced vascular ROS as well as markers of inflammation and plaque necrotic core area.

Conclusions/interpretation: Diabetes promotes pro-inflammatory immune responses in the aortic sinus and its associated lymphoid tissue. These changes are associated with increased ROS production by NOX. Blockade of NOX-derived ROS using the NOX inhibitor GKT137831 is associated with attenuation of these changes in the immune response and reduces the diabetes-accelerated development of atherosclerotic plaques in Apoe(-/-) mice.

Citing Articles

Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.

Karakasis P, Theofilis P, Patoulias D, Vlachakis P, Antoniadis A, Fragakis N Int J Mol Sci. 2025; 26(5).

PMID: 40076813 PMC: 11900163. DOI: 10.3390/ijms26052196.

Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.

Khan A, Jandeleit-Dahm K Nat Rev Cardiol. 2025; .

PMID: 39805949 DOI: 10.1038/s41569-024-01115-w.

Osteocyte mitochondria regulate angiogenesis of transcortical vessels.

Liao P, Chen L, Zhou H, Mei J, Chen Z, Wang B Nat Commun. 2024; 15(1):2529.

PMID: 38514612 PMC: 10957947. DOI: 10.1038/s41467-024-46095-0.

Pan-Nox inhibitor treatment improves renal function in aging murine diabetic kidneys.

Park J, Yoon S, Ghee J, Yoo J, Cha J, Kang Y Kidney Res Clin Pract. 2023; 43(6):763-773.

PMID: 37559225 PMC: 11615449. DOI: 10.23876/j.krcp.23.004.

Inhibition of NADPH Oxidase (NOX) 2 Mitigates Colitis in Mice with Impaired Macrophage AMPK Function.

Banskota S, Wang H, Kwon Y, Gautam J, Haq S, Grondin J Biomedicines. 2023; 11(5).

PMID: 37239114 PMC: 10216132. DOI: 10.3390/biomedicines11051443.

References

1.

Thim T, Hagensen M, Bentzon J, Falk E . From vulnerable plaque to atherothrombosis. J Intern Med. 2008; 263(5):506-16. DOI: 10.1111/j.1365-2796.2008.01947.x. View

2.

Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T . Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis. 2006; 193(2):328-34. DOI: 10.1016/j.atherosclerosis.2006.09.016. View

3.

Guzik T, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P . Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol. 2005; 26(2):333-9. DOI: 10.1161/01.ATV.0000196651.64776.51. View

4.

Ding H, Hashem M, Triggle C . Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. Eur J Pharmacol. 2007; 561(1-3):121-8. DOI: 10.1016/j.ejphar.2006.12.034. View

5.

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

6.

Kunsch C, Medford R . Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999; 85(8):753-66. DOI: 10.1161/01.res.85.8.753. View

7.

Elmarakby A, Loomis E, Pollock J, Pollock D . NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension. 2004; 45(2):283-7. DOI: 10.1161/01.HYP.0000153051.56460.6a. View

8.

van der Wal A, Becker A, van der Loos C, Das P . Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994; 89(1):36-44. DOI: 10.1161/01.cir.89.1.36. View

9.

Lindley S, Dayan C, Bishop A, Roep B, Peakman M, Tree T . Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2004; 54(1):92-9. DOI: 10.2337/diabetes.54.1.92. View

10.

Krege J, Hodgin J, Hagaman J, SMITHIES O . A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995; 25(5):1111-5. DOI: 10.1161/01.hyp.25.5.1111. View

11.

Gray S, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano A . NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation. 2013; 127(18):1888-902. DOI: 10.1161/CIRCULATIONAHA.112.132159. View

12.

Cybulsky M, Iiyama K, Li H, Zhu S, Chen M, Iiyama M . A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001; 107(10):1255-62. PMC: 209298. DOI: 10.1172/JCI11871. View

13.

Hansson G, Hermansson A . The immune system in atherosclerosis. Nat Immunol. 2011; 12(3):204-12. DOI: 10.1038/ni.2001. View

14.

Zhou X, Nicoletti A, Elhage R, Hansson G . Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000; 102(24):2919-22. DOI: 10.1161/01.cir.102.24.2919. View

15.

Aoyama T, Paik Y, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L . Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology. 2012; 56(6):2316-27. PMC: 3493679. DOI: 10.1002/hep.25938. View

16.

Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M . Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002; 106(16):2067-72. DOI: 10.1161/01.cir.0000034509.14906.ae. View

17.

Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A . Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation. 2013; 127(9):1028-39. DOI: 10.1161/CIRCULATIONAHA.112.001347. View

18.

Kanter J, Bornfeldt K . Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators. Trends Endocrinol Metab. 2012; 24(3):137-44. PMC: 3578033. DOI: 10.1016/j.tem.2012.10.002. View

19.

Griendling K, Ushio-Fukai M . NADH/NADPH Oxidase and Vascular Function. Trends Cardiovasc Med. 2011; 7(8):301-7. DOI: 10.1016/S1050-1738(97)00088-1. View

20.

McLaren J, Ramji D . Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2008; 20(2):125-35. DOI: 10.1016/j.cytogfr.2008.11.003. View